ArticlePediatrics international : official journal of the Japan Pediatric Society
Resurgence of Macrolide-Resistant Mycoplasma pneumoniae After the COVID-19 Pandemic at a Children's Hospital in Japan.
Article in Pediatrics international : official journal of the Japan Pediatric Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycoplasma pneumoniae is a leading cause of pediatric community-acquired pneumonia. Macrolide-resistant M. pneumoniae (MRMP) emerged in East Asia in the 2000s and was once highly prevalent in Japan. However, its epidemiology in Japan following the coronavirus disease 2019 (COVID-19) pandemic is unclear.
methodsThe present, single-center, retrospective study, conducted at a tertiary children's hospital in Tokyo, investigated the post-pandemic prevalence of MRMP and compared the clinical features of MRMP and macrolide-susceptible M. pneumoniae (MSMP). Patients aged ≤ 18 years who were positive for M. pneumoniae on polymerase chain reaction (PCR) between April 2020 and March 2025 were enrolled. MRMP was defined by macrolide-resistance mutations detected using a point-of-care, PCR-based assay. The proportion of patients with MRMP and the clinical characteristics of the MRMP and MSMP cohorts were analyzed.
resultsIn total, 272 patients had a M. pneumoniae infection, and 191 (70.2%) patients were classified into the MRMP group. A marked resurgence of M. pneumoniae infections, of which MRMP comprised 87% of the cases, was observed in April 2024 and peaked in October 2024. Among hospitalized patient (52/272, 19.1%), MRMP group were more likely to require oxygen (89% vs. 43%, p = 0.0015), and experience respiratory complications (47% vs. 7.1%, p = 0.019) than MSMP group.
conclusionMRMP reemerged as the predominant strain in Tokyo following the COVID-19 pandemic and may be associated with greater severity and recalcitrance to treatment. Therefore, monitoring its prevalence and adjusting the antibiotic strategy are crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.